Clinical Trials Logo

Scleroderma, Diffuse clinical trials

View clinical trials related to Scleroderma, Diffuse.

Filter by:

NCT ID: NCT00005317 Completed - Lung Diseases Clinical Trials

Idiopathic Pulmonary Fibrosis--Pathogenesis and Staging - SCOR in Occupational and Immunological Lung Diseases

Start date: December 1986
Phase: N/A
Study type: Observational

To conduct cross-sectional and longitudinal studies of patients with idiopathic pulmonary fibrosis (IPF) and patients with progressive systemic sclerosis (PSS), with and without associated lung disease.

NCT ID: NCT00004786 Completed - Systemic Sclerosis Clinical Trials

Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis

Start date: December 1995
Phase: Phase 3
Study type: Interventional

OBJECTIVES: I. Evaluate the safety and efficacy of oral iloprost, a prostacyclin analog, in patients with Raynaud's phenomenon secondary to systemic sclerosis.

NCT ID: NCT00004563 Completed - Lung Diseases Clinical Trials

Scleroderma Lung Disease

SLS
Start date: August 1999
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy and safety of cyclophosphamide versus placebo for the prevention and progression of symptomatic pulmonary disease in patients with systemic sclerosis.

NCT ID: NCT00004380 Completed - Systemic Sclerosis Clinical Trials

Phase II Study of Recombinant Relaxin for Progressive Systemic Sclerosis

Start date: December 1991
Phase: Phase 2
Study type: Interventional

OBJECTIVES: I. Determine whether parenteral relaxin improves skin tightness, Raynaud's phenomenon, digital morbidity, and digital ulcers in a patient with progressive systemic sclerosis (scleroderma). II. Determine whether relaxin decreases collagen production by fibroblasts in vivo and cultured from skin biopsies.

NCT ID: NCT00001330 Completed - Autoimmune Diseases Clinical Trials

Study of Silicone-Associated Connective Tissue Diseases

Start date: November 1992
Phase: N/A
Study type: Observational

This study will examine the possible relationship between silicone implants or injections and the connective tissue diseases scleroderma and myositis. It will explore whether certain factors in the blood or the immune system or other factors are involved in the development of these diseases following silicone implantation or injection. Men and women 18 years of age and older who meet the following criteria may be eligible for this study: Group 1-Patients who have had silicone implants or injections and who later developed scleroderma or myositis Group 2-Patients with scleroderma or myositis who have not had silicone implants or injections Group 3-Healthy volunteers who have had silicone implants or injections and did not develop symptoms or other medical features of connective tissue disorders. Participants will have a thorough history and physical examination, blood and urine tests, chest X-ray and lung function tests. In addition, patients will complete a questionnaire about their procedure (including information such as the types of implanted devices and injections, reason for the procedure, post-operative complications, other illnesses or medical conditions present before and after the procedure, etc.).